Biography and Research Information
OverviewAI-generated summary
Milan Bilami's research interests include the study of cancer recurrence, particularly in the context of head and neck cancers. Their work has involved investigating therapeutic vaccines, such as PepCan, as a potential strategy to reduce recurrence rates following treatment. This research is situated within a broader effort to understand and improve outcomes for cancer patients.
Bilami has engaged in collaborative research at the University of Arkansas for Medical Sciences, co-authoring publications with David W. Ussery, Jennifer L. Faulkner, Yong‐Chen Lu, and Jumin Sunde. Their publication record includes a 2026 article detailing a Phase I/II clinical trial for a human papillomavirus therapeutic vaccine aimed at head and neck cancer recurrence.
Metrics
- Publications: 1
Selected Publications
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
Collaboration Network
Top Collaborators
Emily Ward Bivens
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Omar Atiq
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Teresa Evans
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Ginger Brown
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jasmine Crane
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Rangaswamy Govindarajan
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Aaron Johnson
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Alongkorn Kurilung
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Oxana P. Lazarenko
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Yong-Chen William Lu
University of Arkansas for Medical Sciences (US)
1 shared publication
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Keanna Marsh
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
M Moreno
University of Arkansas for Medical Sciences (US)
1 shared publication
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Similar Researchers
Based on overlapping research topics
Emre Duval
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Keanna Marsh
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Mindy Wilman
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Aaron Johnson
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Yong-Chen William Lu
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy
Teresa Evans
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Vaccine Coverage and Hesitancy